FDA to amend MQSA rules for x-ray
X-ray equipment designed for various applications may be used for mammography, according to a new draft compliance document of the Mammography Quality Standards Act (MQSA) issued by the Food and Drug Administration on Aug. 27. The document states that
X-ray equipment designed for various applications may be used for mammography, according to a new draft compliance document of the Mammography Quality Standards Act (MQSA) issued by the Food and Drug Administration on Aug. 27. The document states that mammography procedures may be performed on general x-ray devices, provided that the devices meet all applicable MQSA requirements and have been optimized for mammography.
Final MQSA rules were published in October 1997 and amended a month later. The August guidance clarifies the final guidances section 21 CFR 900.12, which prohibits the use of general-purpose equipment for mammography imaging, requiring that x-ray equipment be specifically designed for mammography uses. The FDA will accept written comment on the draft guidance until Nov. 25.
When final, the draft compliance document may have beneficial effects for companies such as Fuji, which has had to hold back from market a mammography module for its general-purpose computed radiography systems. Fujis system had originally been cleared for mammography applications, but when the FDA began to review digital mammography guidance with greater scrutiny, it asked the company to remove that capability from the system, according to Fuji executives. When the MQSA guidance becomes final in April 1999, commercializing general x-ray systems for mammography uses may get easier.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
